Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-64041809 |
| Synonyms | |
| Therapy Description |
Opolimogene Capmilisbac (JNJ-64041809) is an attenuated strain of Listeria monocytogenes encoding multiple tumor antigens which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-64041809 | JNJ-809|Opolimogene Capmilisbac|ADU-741 | Opolimogene Capmilisbac (JNJ-64041809) is an attenuated strain of Listeria monocytogenes encoding multiple tumor antigens which may stimulate anti-tumor immune response (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02625857 | Phase I | JNJ-64041809 | Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer | Completed | USA | 0 |